These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 21205154

  • 1. Novel molecular therapies in hepatocellular carcinoma.
    Faivre S, Bouattour M, Raymond E.
    Liver Int; 2011 Jan; 31 Suppl 1():151-60. PubMed ID: 21205154
    [Abstract] [Full Text] [Related]

  • 2. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 3. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep 01; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 4. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M, Ueshima K.
    Oncology; 2010 Jul 01; 78 Suppl 1():154-66. PubMed ID: 20616599
    [Abstract] [Full Text] [Related]

  • 5. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
    Ibrahim N, Yu Y, Walsh WR, Yang JL.
    Oncol Rep; 2012 May 01; 27(5):1303-11. PubMed ID: 22323095
    [Abstract] [Full Text] [Related]

  • 6. Signaling pathways in hepatocellular carcinoma.
    Sia D, Villanueva A.
    Oncology; 2011 May 01; 81 Suppl 1():18-23. PubMed ID: 22212931
    [Abstract] [Full Text] [Related]

  • 7. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L, Santoro A.
    Dig Liver Dis; 2010 Jul 01; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [Abstract] [Full Text] [Related]

  • 8. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

  • 9. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V, Barbare JC, Rosmorduc O, Groupe de travail carcinome hépatocellulaire Prodige-Afef.
    Gastroenterol Clin Biol; 2008 Jan 01; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract] [Full Text] [Related]

  • 10. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
    Lord R, Suddle A, Ross PJ.
    Int J Clin Pract; 2011 Feb 01; 65(2):182-8. PubMed ID: 21235699
    [Abstract] [Full Text] [Related]

  • 11. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
    Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L.
    Eur J Gastroenterol Hepatol; 2010 Apr 01; 22(4):391-8. PubMed ID: 19940784
    [Abstract] [Full Text] [Related]

  • 12. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY, Park JW.
    Dig Dis; 2011 Apr 01; 29(3):303-9. PubMed ID: 21829021
    [Abstract] [Full Text] [Related]

  • 13. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
    Lee JM, Han KH.
    Oncology; 2010 Jul 01; 78 Suppl 1():167-71. PubMed ID: 20616600
    [Abstract] [Full Text] [Related]

  • 14. Molecular targeting for treatment of advanced hepatocellular carcinoma.
    Song IH.
    Korean J Hepatol; 2009 Sep 01; 15(3):299-308. PubMed ID: 19783879
    [Abstract] [Full Text] [Related]

  • 15. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA, Galle PR.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):615-29. PubMed ID: 20374038
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.
    Anticancer Drugs; 2010 Mar 01; 21(3):326-32. PubMed ID: 20016366
    [Abstract] [Full Text] [Related]

  • 17. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
    Kudo M.
    Dig Dis; 2011 Mar 01; 29(3):289-302. PubMed ID: 21829020
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R.
    Oncologist; 2009 Jan 01; 14(1):95-100. PubMed ID: 19144678
    [Abstract] [Full Text] [Related]

  • 19. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Jan 01; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 20. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
    Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, Borg C.
    J Clin Oncol; 2011 Apr 20; 29(12):e330-2. PubMed ID: 21263091
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.